naltrexone has been researched along with amitriptyline in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 10 (62.50) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Strassburg, CP; Tukey, RH | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA | 1 |
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gray, AM; Sewell, RD; Spencer, PS | 1 |
| Grinenko, AIa; Krupitskiĭ, EM; Zvartau, EE | 1 |
| Bonnet, U; Overlack, M; Schürks, M | 1 |
| Buonopane, A; Petrakis, IL | 1 |
| Bansal, D; Bhansali, AK; Chakrabarti, A; Dutta, P; Hota, D; Srinivasan, A | 1 |
| Alto, M; Giusto, A; Greene, MC; Johnson, RM; Kane, J; Lovero, K; McClendon, J; Nicholson, T; Stockton, M; Tol, WA; Wainberg, ML | 1 |
| DeSanto, K; Huang, H; Lyon, C; Radi, R; Rivera, J | 1 |
5 review(s) available for naltrexone and amitriptyline
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacotherapy of alcohol use disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Amitriptyline; Antidepressive Agents, Tricyclic; Comorbidity; Disulfiram; Dopamine; Drug Interactions; Ethanol; Female; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Male; Mental Disorders; Naltrexone; Narcotics; Serotonin; Taurine | 2005 |
Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries.
Topics: Acamprosate; Alcoholism; Amitriptyline; Developing Countries; Disulfiram; Humans; Male; Mirtazapine; Naltrexone; Ondansetron; Topiramate | 2023 |
3 trial(s) available for naltrexone and amitriptyline
| Article | Year |
|---|---|
[Pharmacotherapy in heroin addiction: pharmacological approaches to remission stabilization and recurrence prevention].
Topics: Adult; Amitriptyline; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Double-Blind Method; Drug Therapy, Combination; Heroin Dependence; Humans; Mood Disorders; Naltrexone; Narcotic Antagonists; Patient Compliance; Placebos; Recurrence; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 2003 |
Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: A randomized, double-blind, active-control, crossover clinical trial.
Topics: Amitriptyline; Analgesics, Non-Narcotic; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Pain; Pain Measurement | 2021 |
Is low-dose naltrexone effective in chronic pain management?
Topics: Amitriptyline; Fibromyalgia; Humans; Naltrexone; Pain; Pain Management | 2023 |
8 other study(ies) available for naltrexone and amitriptyline
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations | 2002 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds.
Topics: Abdominal Muscles; Acetic Acid; Amitriptyline; Analgesics; Animals; Antidepressive Agents; Cyclobutanes; Dothiepin; Male; Maprotiline; Mice; Muscle Contraction; Naloxone; Naltrexone; Narcotic Antagonists; Neprilysin; Neurotransmitter Uptake Inhibitors; Opioid Peptides; Pain Measurement; Paroxetine; Protease Inhibitors; Receptors, Opioid; Selective Serotonin Reuptake Inhibitors; Thiorphan | 1998 |
Naltrexone treatment of combined alcohol and opioid dependence: deterioration of co-morbid major depression.
Topics: Alcoholism; Amitriptyline; Depressive Disorder, Major; Ethanol; Humans; Male; Middle Aged; Morphine; Morphine Dependence; Naltrexone; Narcotics; Severity of Illness Index; Substance Withdrawal Syndrome | 2005 |